-+ 0.00%
-+ 0.00%
-+ 0.00%

Eisai’s Leqembi cuts Alzheimer’s progression risk 36% versus ADNI in five-year study

PUBT·11/16/2026 23:02:03
Eisai’s Leqembi cuts Alzheimer’s progression risk 36% versus ADNI in five-year study
  • Eisai and Biogen presented five-year Leqembi results from the Clarity AD extension at the 2026 Clinical Trials on Alzheimer's Disease conference.
  • Continuous treatment slowed Alzheimer's progression compared with natural-history data, with benefits increasing over time.
  • Patients treated at earlier biological stages showed sustained benefits in cognition and daily functioning.
  • No new safety findings emerged over five years; brain swelling occurred most frequently during the first six months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611161800PR_NEWS_USPR_____NY99073) on November 16, 2026, and is solely responsible for the information contained therein.